Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J B Haanen

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2009
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival modelsJ S Vermaat, I van der Tweel, N Mehra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trialL Bergmann, L Albiges, M Ahrens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 5, 2021
<sup>89</sup>Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancerI C Kok, J S Hooiveld, P P van de Donk, et al.
British Journal of Cancer|April 28, 2025
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapyE J van Dijk, H H Nienhuis, A J M van den Eertwegh, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registryA Özkan, E Kapiteijn, F van den Bos, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2009
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival modelsJ S Vermaat, I van der Tweel, N Mehra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinomaN Agarwal, J Brugarolas, P Ghatalia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trialL Bergmann, L Albiges, M Ahrens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 5, 2021
<sup>89</sup>Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancerI C Kok, J S Hooiveld, P P van de Donk, et al.
British Journal of Cancer|April 28, 2025
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapyE J van Dijk, H H Nienhuis, A J M van den Eertwegh, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2024
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registryA Özkan, E Kapiteijn, F van den Bos, et al.
Pageof 3